Results 281 to 290 of about 99,653 (320)
Some of the next articles are maybe not open access.
The biochemistry and physiology of urokinase
The American Journal of Cardiology, 1960Abstract Development of methods for isolating, purifying and assaying urokinase, the urinary enzyme activator of plasma profibrinolysin, is described. Properties of the enzyme are given and the unit of activity is defined and related to units of other workers.
David R. Celander, M. Mason Guest
openaire +3 more sources
Urokinase in Pulmonary Embolism
New England Journal of Medicine, 1967THE use of thrombolytic enzymes or their activators has been proposed as a treatment of thromboembolic diseases such as pulmonary embolism. Using streptokinase as the plasminogen activator, Johnson and McCarty1 demonstrated the efficacy of thrombolytic therapy in the lysis of venous thrombi induced in human volunteers.
Ursula Scheffel +6 more
openaire +3 more sources
The Immunoassay of Human Urokinase
Thrombosis and Haemostasis, 1969SummaryUrokinase with an activity of 45,200 CTA nnits/mg was used in 0.4 mg amounts with Freund’s adjuvant to immunize four individual rabbits by two injections spaced 4 weeks apart. All antisera were titrated for inhibition of urokinase activation of plasminogen, for double diffusion in Agarose, and for immunoelectrophoresis. Against constant portions
Anne P. Ball +4 more
openaire +3 more sources
Urokinase and Single-Chain Urokinase-Type Plasminogen Activator (Pro-urokinase) [PDF]
, 2001 The discovery of urokinase (UK) is described in chap. 4. The UK in urine is not a waste product as shown by studies of the fate of intravenous injections of UK, which was found not to be excreted by the kidney (Fletcher et al. 1965). Instead, it is secreted by renal tubular cells (Sappino et al.
openaire +1 more source
JAMA: The Journal of the American Medical Association, 1974
To the Editor.— I was interested in the fortunately brief report on the use of urokinase in the treatment of acute myocardial infarction (228:1629, 1974). Although I don't feel inclined to call a press conference, I think it might be in order to set the record straight. I am referring to Dr. M. S.
Richard D. Sautter +2 more
openaire +2 more sources
To the Editor.— I was interested in the fortunately brief report on the use of urokinase in the treatment of acute myocardial infarction (228:1629, 1974). Although I don't feel inclined to call a press conference, I think it might be in order to set the record straight. I am referring to Dr. M. S.
Richard D. Sautter +2 more
openaire +2 more sources
Urokinase/Urokinase Receptor-Mediated Signaling in Cancer
2007Experimental oncogenic transformation or in spontaneous human cancers, mitogenesis and expression of fibrinolytic components such as urokinase (uPA), its receptor (uPAR), and its major inhibitor plasminogen activator inhibtor-1 (PAI-1) or -2 (PAI-2) are activated by common signaling mechanisms.
Sreerama Shetty, Steven Idell
openaire +2 more sources
Fibrinolytic and fibrinogenolytic effects of acyl urokinase and urokinase combinations in vitro
Russian Journal of Bioorganic Chemistry, 2006The in vitro thrombolytic and side effects of double-strand urokinase-type plasminogen activator (tcu-PA), p-guanidinobenzoyl tcu-PA (GB-tcu-PA), and their combinations were compared. The reversible blocking of the active site stabilizes GB-tcu-PA in human plasma and results in longer thrombolysis and lesser side effects than those of tcu-PA.
L.I. Mukhametova +2 more
openaire +3 more sources
Studies with a Preparation of Urokinase
Thrombosis and Haemostasis, 1967SummaryThe evidence presented in this paper shows that though less coagulative than urokinase (Leo), urokinase (Abbott), both in vitro and in vivo, has coagulant activity. Further, evidence has been presented that urokinase may accelerate platelet aggregation.
Patricia A. Wilson +3 more
openaire +3 more sources
The urokinase plasminogen activator system: a target for anti-cancer therapy.
Current Cancer Drug Targets, 2009The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2).
S. Ulisse +3 more
semanticscholar +1 more source
The Urokinase Receptor Interactome
Current Pharmaceutical Design, 2011The urokinase receptor (uPAR) was originally identified as the membrane receptor of the serine protease urokinase (uPA), thereby implicated in the plasminogen activation cascade and regulation of pericellular proteolysis. Later on, vitronectin was showed to be another major ligand providing uPAR with a role in cell adhesion.
Gabriele Eden +4 more
openaire +3 more sources